$1.19
+0.05 (+4.39%)
Open$1.16
Previous Close$1.14
Day High$1.20
Day Low$1.13
52W High$23.70
52W Low$1.11
Volume—
Avg Volume4.64M
Market Cap3.88M
P/E Ratio—
EPS$-28.37
SectorBiotechnology
Analyst Ratings
Strong Buy
7 analysts
Price Target
+3,158.8% upside
Current
$1.19
$1.19
Target
$38.78
$38.78
$26.82
$38.78 avg
$44.92
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 2.63M | 2.53M | 2.93M |
| Net Income | 21.2K | 20.0K | 19.6K |
| Profit Margin | 0.8% | 0.8% | 0.7% |
| EBITDA | 30.9K | 30.5K | 37.6K |
| Free Cash Flow | 17.8K | 22.0K | 24.1K |
| Rev Growth | -5.2% | +23.9% | +20.0% |
| Debt/Equity | 0.27 | 0.26 | 0.26 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $217.49 | +2.05% | 166.6 | 397.77B |
| AMGN | Amgen Inc | $351.85 | +0.82% | 24.7 | 190.40B |
| GILD | Gilead Sciences Inc | $139.37 | +2.22% | 19.6 | 166.66B |
| VRTX | Vertex Pharmaceuticals Inc | $446.54 | +0.76% | 29.1 | 114.87B |
| REGN | Regeneron Pharmaceuticals | $772.64 | +3.12% | 17.9 | 80.50B |
| ALNY | Alnylam Pharmaceuticals Inc | $330.87 | +4.68% | 139.7 | 43.84B |